JRH bought for $370 million

Sigma-Aldrich Corporation has signed an agreement to acquire the JRH Biosciences division of CSL for $370 million in cash.

Sigma-Aldrich Corporation, the global life sciences company, has signed an agreement to acquire the JRH Biosciences division (JRH) of CSL Limited for $370 million in cash.

JRH is a global supplier of cell culture and sera products to the biopharmaceutical industry with 2004 sales of approximately $150 million, which are expected to increase by approximately 10% in 2005.

JRH is headquartered in Lenexa, Kansas, and has major manufacturing facilities in the US, Europe and Australia. The company, which employs around 400 staff, also has serum collection and processing centres in the US and Australia.

The company’s product lines include sera, cell culture media used in the production of therapeutic proteins, reagent growth factors and biological material containers.

The deal has been approved by the boards of directors of both companies and, subject to regulatory approvals and other customary terms and conditions, is expected to close in the first quarter of 2005.

On the web